Literature on sermorelin, a GHRH(1-29) analog used in growth hormone deficiency diagnostics and research settings.
Also called Sermorelin, GHRH 1-29, growth hormone releasing factor 1-29
Sources: 2 new papers · 5 key papers · updated Oct 20, 2026
Unverified · drafted by AI from the sources cited below
Sermorelin is the biologically active fragment of human growth hormone-releasing factor, consisting of GHRH(1-29)-amide.1 This N-terminal sequence is identical in several mammalian species, such as human, pig, and cattle.
Sermorelin is used to diagnose patients with GROWTH HORMONE deficiency.1
Sermorelin is used to treat patients with GROWTH HORMONE deficiency.1
Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction
Proceedings of the National Academy of Sciences — Rieger A
27 citations · 2021 · among the most cited on Sermorelin
Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity
Peptides — Cai R
27 citations · 2021 · among the most cited on Sermorelin
Agonist of growth hormone–releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury
Proceedings of the National Academy of Sciences — Cen L
23 citations · 2021 · among the most cited on Sermorelin
Advances in the detection of growth hormone releasing hormone synthetic analogs
Drug Testing and Analysis — Memdouh S
22 citations · 2021 · among the most cited on Sermorelin
Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells
Frontiers in Immunology — Granato G
19 citations · 2023 · among the most cited on Sermorelin
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.